<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638222</url>
  </required_header>
  <id_info>
    <org_study_id>UTHSC-08</org_study_id>
    <nct_id>NCT00638222</nct_id>
  </id_info>
  <brief_title>Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease</brief_title>
  <official_title>Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toledo Health Science Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toledo Health Science Campus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate effectiveness of Carvedilol CR on Micro T-Wave Alternans in high risk hypertensives
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effect of Carvedilol CR on Micro T-Wave Alternans will be assessed in 30 hypertensives
      with stage 4 or 5 chronic kidney disease utilizing a cross-over design and contrasting no
      treatment against active treatment periods of 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Micro T- Wave Alternans</measure>
    <time_frame>week 1, 8, 11, 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidized LDL</measure>
    <time_frame>week 1, 8, 11, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>week 1, 8, 11, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma C-reactive Protein</measure>
    <time_frame>week 1, 8, 11, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cardiac Troponin T</measure>
    <time_frame>week 1, 8, 11, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma NT-pro BNP</measure>
    <time_frame>week 1, 8, 11, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma F2-isoprostanes</measure>
    <time_frame>week 1, 8, 11, 18</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Vascular Disease</condition>
  <condition>Kidney Disease</condition>
  <arm_group>
    <arm_group_label>All Study Participants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Carvedilol and Placebo</intervention_name>
    <description>All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.</description>
    <arm_group_label>All Study Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults age 18 and older

          -  Chronic kidney disease

          -  Must be able to do stress test

        Exclusion Criteria:

          -  Must not be mentally disabled

          -  Unable to provide informed consent

          -  Unable or unwilling to comply with study protocol or procedures

          -  Pregnancy or unknown pregnancy status in female of childbearing potential

          -  Participation in any drug trial during the study period

          -  Prior enrollment in this study

          -  Active liver disease

          -  Currently on β-blocker medication at the time of enrollment

          -  Known history of asthma exacerbation with β-blocker therapy

          -  Second or third degree AV nodal block or bradycardia with resting heart rate &lt;50 bpm

          -  Prior allograft organ transplantation

          -  Planned allograft transplantation reasonably foreseen within the active treatment
             period

          -  Electrocardiographic left or right bundle branch block

          -  Permanent implanted pacemaker

          -  Atrial fibrillation

          -  Ongoing treatment with any of the following medications: sotalol (Betapace), azimilide
             (Stedicor), quinidine (Quinidex), disopyramide (Norpace), dofetilide (Tikosyn),
             ibutilide (Corvert), procainamide (Procanbid), bepridil (Vascor), amiodarone
             (Cordarone), clarithromycin (Biaxin), erythromycin (Eryc), halofantrine (Halfan),
             pentamidine (Pentam), sparfloxacin (Zagam), domperidone (Motilium), droperidol
             (Inapsine), chlorpromazine (Thorazine), haloperidol (Haldol), mesoridazine (Serentil),
             thioridazine (Mellaril), pimozide (Orap), arsenic trioxide (Trisenox), cisapride
             (Propulsid), lidoflazine (Clinium), and methadone (Dolophine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Cooper, , MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toledo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Toledo, Health Science Campus</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <results_first_submitted>July 8, 2014</results_first_submitted>
  <results_first_submitted_qc>November 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 13, 2014</results_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toledo Health Science Campus</investigator_affiliation>
    <investigator_full_name>Christopher Cooper, MD</investigator_full_name>
    <investigator_title>Professor, Interim Chair/Dir Cardiovas Research Cntr</investigator_title>
  </responsible_party>
  <keyword>Carvedilol</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>Vascular Disease</keyword>
  <keyword>Kidney</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carvedilol Then Placebo</title>
          <description>Subject will receive Carvedilol over 8 weeks then receive Placebo for the 8 weeks following.
Carvedilol: Subject will receive Carvedilol over 8 weeks then receive Placebo for the 8 weeks following.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Study Drug</title>
          <description>Subjects will receive placebo for 8 weeks then be given study drug for 8 more.
Placebo: Subjects will receive placebo for 8 weeks then be given study drug for 8 more.</description>
        </group>
        <group group_id="P3">
          <title>All Participants</title>
          <description>All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carvedilol Then Placebo</title>
          <description>Subject will receive Carvedilol over 8 weeks then receive Placebo for the 8 weeks following.
Carvedilol: Subject will receive Carvedilol over 8 weeks then receive Placebo for the 8 weeks following.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Then Study Drug</title>
          <description>Subjects will receive placebo for 8 weeks then be given study drug for 8 more.
Placebo: Subjects will receive placebo for 8 weeks then be given study drug for 8 more.</description>
        </group>
        <group group_id="B3">
          <title>All Study Participants</title>
          <description>All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="55" spread="15"/>
                    <measurement group_id="B4" value="55" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Micro T- Wave Alternans</title>
        <time_frame>week 1, 8, 11, 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carvedilol Then Placebo</title>
            <description>Subject will receive Carvedilol over 8 weeks then receive Placebo for the 8 weeks following.
Carvedilol: Subject will receive Carvedilol over 8 weeks then receive Placebo for the 8 weeks following.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Then Study Drug</title>
            <description>Subjects will receive placebo for 8 weeks then be given study drug for 8 more.
Placebo: Subjects will receive placebo for 8 weeks then be given study drug for 8 more.</description>
          </group>
        </group_list>
        <measure>
          <title>Micro T- Wave Alternans</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidized LDL</title>
        <time_frame>week 1, 8, 11, 18</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin-6</title>
        <time_frame>week 1, 8, 11, 18</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma C-reactive Protein</title>
        <time_frame>week 1, 8, 11, 18</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cardiac Troponin T</title>
        <time_frame>week 1, 8, 11, 18</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma NT-pro BNP</title>
        <time_frame>week 1, 8, 11, 18</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma F2-isoprostanes</title>
        <time_frame>week 1, 8, 11, 18</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Carvedilol Then Placebo</title>
          <description>Subject will receive Carvedilol over 8 weeks then receive Placebo for the 8 weeks following.
Carvedilol: Subject will receive Carvedilol over 8 weeks then receive Placebo for the 8 weeks following.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Then Study Drug</title>
          <description>Subjects will receive placebo for 8 weeks then be given study drug for 8 more.
Placebo: Subjects will receive placebo for 8 weeks then be given study drug for 8 more.</description>
        </group>
        <group group_id="E3">
          <title>All Study Participants</title>
          <description>All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Low Blood Pressure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fluid Retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Right Groin Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at Dialysis Catheter Site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dialysis Catheter Placed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lower Extremity Angiogram</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to poor enrollment leading to small number of subjects to be analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christopher Cooper, MD</name_or_title>
      <organization>The University of Toledo, HSC</organization>
      <phone>419.383.6030</phone>
      <email>christopher.cooper@utoledo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

